Investors & Media
Jade Biosciences is focused on developing innovative, best-in-class therapies to address critical unmet needs in autoimmune diseases.
Our lead candidate, JADE101, is designed to inhibit the cytokine APRIL (A Proliferation-Inducing Ligand) and is being developed for the treatment of immunoglobulin A nephropathy (IgAN), a chronic kidney disease that can impair kidney function over time. JADE101 aims to reduce harmful IgA antibodies, lower proteinuria (a key marker of kidney damage), and preserve long-term kidney function.
Jade’s pipeline also includes JADE201, an anti-BAFF-R (B-cell activating factor receptor) monoclonal antibody, and JADE301, an anti-IFN-β (interferon beta) monoclonal antibody.
About Us
Experience across every stage.
We are scientists, clinicians, and company builders with expertise across every stage of drug development, from target selection to commercial launch.
